Recent evidence indicates an important role for the retinoblastoma (RB) tumor suppressor in the development of castration resistance in prostate cancer. In this Review, the authors describe the current state of knowledge regarding the implications of RB loss for disease progression, and consider the potential opportunities for developing RB as a metric with which to predict therapeutic response.
- Ana Aparicio
- Robert B. Den
- Karen E. Knudsen
